Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Consequences of neurologic lesions assessed by Barthel Index after Botox(®) injection may be underestimated.
Reply: Microcystic macular degeneration from optic neuropathy: not inflammatory, not trans-synaptic degeneration.
Sjögren's syndrome and multiple sclerosis: Two sides of the same coin?
[A case of early systemic lupus erythematosus complicated with optic neuritis].
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
Neurotoxocarosis alters myelin protein gene transcription and expression.
Inactivation of Protein Tyrosine Phosphatase Receptor Type Z by Pleiotrophin Promotes Remyelination through Activation of Differentiation of Oligodendrocyte Precursor Cells.
Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
Efficacy of Tryptophan Immunoadsorption Plasmapheresis for Neuromyelitis Optica in Two Cases.
The immunomodulatory oligodendrocyte.
Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36.
The Non-Obese Diabetic Mouse Strain as a Model to Study CD8(+) T Cell Function in Relapsing and Progressive Multiple Sclerosis.
Primary spinal oligoastrocytoma mimicking longitudinally extensive transverse myelitis.
Bi-Allelic TCRα or β Recombination Enhances T Cell Development but Is Dispensable for Antigen Responses and Experimental Autoimmune Encephalomyelitis.
Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation.
Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis.
Cell-Based Reparative Therapies for Multiple Sclerosis.
Group specific vein-atlasing: An application for analyzing the venous system under normal and multiple sclerosis conditions.
Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis.
The role of dendritic cells in autoimmunity.
Cerebrospinal fluid pleocytosis in multiple sclerosis patients with lesions showing reduced diffusion.
High CD6 and low chemokine receptor expression on peripheral blood lymphocytes correlates with MRI gadolinium enhancement in MS.
Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability.
Stability of rating scale response category interpretations in neurological disorders.
Pages
« first
‹ previous
…
560
561
562
563
564
565
566
567
568
…
next ›
last »